A look at Global Blood Therapeutics' Sickle Cell disease therapeutics including the continued use of Oxbryta and the potential of inclacumabTicker(s): GBT
Institution: Private Practice
- Physician specializing in Hematology and Oncology
- Treats many patients for sickle cell disease and is very familiar with the current treatment landscape as well as drugs in development.
- Active within the hematology community and will be attending the upcoming European Hematology Association conference in Vienna this year.
Could you please describe your clinical practice including how many patients you treat for sickle cell disease and how many you have prescribed Oxbryta for?Added By: sara_admin
Can you speak about your clinical experience with your patients on Oxbyta?Added By: sara_admin
What are your initial thoughts on the abstract of inclacumab?Added By: sara_admin
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.